Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT05135845
Other study ID # APHP201152
Secondary ID
Status Suspended
Phase Phase 2
First received
Last updated
Start date March 22, 2022
Est. completion date October 2025

Study information

Verified date January 2023
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Immunotherapy with anti-PD1 antibodies provides encouraging results on a subset of patients. Capmatinib, a MET inhibitor, has shown an imunomodulatory effect and a synergy with spartalizumab a PD-1 inhibitor. The purpose of this phase II trial is to evaluate the efficacy and safety of the combination of capmatinib + spartalizumab in adult patients with advanced oesogastric adenocarcinoma.


Recruitment information / eligibility

Status Suspended
Enrollment 90
Est. completion date October 2025
Est. primary completion date April 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically documented locally advanced or metastatic oesogastric adenocarcinoma. - Unresectable tumor. - Patients must have received at least one prior systemic chemotherapy based on platinium salt and fluoropyrimidine with documented progression during chemotherapy. - Patients must have received trastuzumab in case of HER2 positive tumor (HER2 +++ or HER2++ and FISH or SISH+) - Determination of tumor MET amplification by FISH available - ECOG Performance Status = 1. - Measurable tumoral disease according to RECIST 1.1 criteria. - Patients must be willing and able to swallow and retain oral medication. - Age =18 years. - Women of childbearing potential and males who are sexually active must agree to follow instructions for method(s) of contraception for the duration of study treatments with Capmatinib and Spartalizumab until 7 days after the last dose of Capmatinib and 150 days after the last dose of Spartalizumab - Consent to participate in the trial after information - Affiliated to a social security system Exclusion Criteria: - Previous treatment with immunotherapy or MET inhibitor - Impossibility to take oral medication - Persistent toxicities related to prior treatment of grade greater than 1 - Presence or history of another malignant disease that has been diagnosed and/or required therapy within the past 3 years. Exceptions to this exclusion include: completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type. - Use of any live vaccines within 4 weeks of initiation of study treatment. - History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs). - History or current interstitial lung disease or non-infectious pneumonitis - Active autoimmune disease or a documented history of autoimmune disease (Patients with vitiligo, controlled type I diabetes mellitus on stable insulin dose, residual autoimmune-related hypothyroidism only requiring hormone replacement or psoriasis not requiring systemic treatment are permitted). - Allogenic bone marrow or solid organ transplant - Uncontrolled active infection - Human Immunodeficiency Virus (HIV) infection - Untreated active Hepatitis B infection (HBsAg positive) (Patients with active hepatitis B (HBsAg positive) may be enrolled provided viral load (HBV DNA) at screening is <100 UI/mL. Patients may receive antiviral treatment with lamivudine, tenofovir, entecavir, or other antiviral agents before the initiation of study treatment to suppress viral replication). - Untreated active hepatitis C (HCV RNA positive) (patients that achieved a sustained virological response after antiviral treatment and show absence of detectable HCV RNA =6 months after cessation of antiviral treatment are eligible) - Untreated or symptomatic central nervous system (CNS) lesion. However, patients are eligible if: a) all known CNS lesions have been treated with radiotherapy or surgery and b) patient remained without evidence of CNS disease progression =4 weeks after treatment and c) patients must be off corticosteroid therapy for =2 weeks - Clinically significant, uncontrolled heart diseases - Recent acute coronary syndrome or unstable ischemic heart disease - Congestive heart failure = Class III or IV as defined by New York Heart Association - Long QT syndrome (> 480 ms in women and 470 ms in men), family history of idiopathic sudden death or congenital long QT syndrome. - Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) =150 mm Hg and/or Diastolic Blood Pressure (DBP) = 100 mm Hg, with or without antihypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening - Surgery less than 4 weeks - Radiotherapy less than 2 weeks - Pregnancy or breastfeeding or women of child-bearing potential, unless they are using highly effective methods of contraception. - Sexually active males unless they use a condom during intercourse while taking capmatinib and for 7 days after stopping treatment and should not father a child in this period. - Participants receiving treatment with strong inducers of CYP3A and could not be discontinued = 1 week prior to the start of treatment. - Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy 7 days prior to planned date of first dose of study treatment. - Patient having out of range laboratory values defined as: - Total bilirubin >2 mg/dL, except for patients with Gilbert's syndrome who are excluded if total bilirubin >3.0 x ULN or direct bilirubin >1.5 x ULN - Alanine aminotransferase (ALT) > 3 x ULN - Aspartate aminotransferase (AST) > 3 x ULN - Coagulation: Prothrombin Time (PT) >4 seconds more than the ULN or International Normalized Ratio (INR) >1.7 - Absolute neutrophil count (ANC) <1.5 x 109/L - Platelet count <75 x 109/L - Hemoglobin <9 g/dL - Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) <45 mL/min - Serum lipase >1 ULN - Cardiac troponin I (cTnI) elevation >2 x ULN - Potassium, Magnesium, Phosphorus, total Calcium (corrected for serum albumin) outside of normal limits (patients may be enrolled if corrected to within normal limits with supplements during screening) - Patients under legal protection - Participation to another interventional study with treatment

Study Design


Intervention

Drug:
Capmatinib
Capmatinib 400mg BID for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity
Spartalizumab
Spartalizumab 300mg Q3W for a maximum of 12 months or until progression, patient's refusal or unacceptable toxicity

Locations

Country Name City State
France Hôpital Jean Minjoz Besançon
France Centre François Leclerc Dijon
France Centre Léon Bérard Lyon
France AP-HP Hôpital Saint Louis Paris
France Hôpital Haut Lévêque Pessac
France Institut Universitaire du Cancer Toulouse
France Institut Gustave Roussy Villejuif

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor response Overall response rate defined as the proportion of patients with at least one objective tumour response (complete or partial) according to response evaluation criteria in solid tumours (RECIST) v1.1 within 6 months. 6 months
Secondary Proportion of unacceptable toxicity of the regimen during the first and second cycles of administration Presence of at least one of (composite endpoint):
Adverse event (AE) grade >3 (NCI-CTCAE v5), at least possibly related to the treatment or unrelated to disease, progression, intercurrent illness, concomitant medications
Non-hematological AE grade =3
Recurring grade 2 pneumonitis, Myocarditis grade =2
Autoimmune hemolytic anemia, hemolytic uremic syndrome, acquired hemophilia grade =3
Guillain-Barre, severe peripheral or autonomic neuropathy, transverse myelitis, encephalitis, aseptic meningitis
Laboratory abnormality grade =3 for >7days (except nephritis grade 3-4, combined elevations of aspartate or alanine transaminase and total bilirubin, hyperglycemia, serum electrolytes/enzymes changes without clinical impact)
Febrile neutropenia, documented infection with absolute neutrophil count<10^9/L, grade 3 neutropenia >7days, grade 4 neutropenia or thrombocytopenia, or bleeding with platelet transfusion
AE with discontinuation >21days
Significant drug-related AE
Day 42
Secondary Proportion of unacceptable toxicity of the regimen during the whole treatment course Presence of at least one of (composite endpoint):
Adverse event (AE) grade >3 (NCI-CTCAE v5), at least possibly related to the treatment or unrelated to disease, progression, intercurrent illness, concomitant medications
Non-hematological AE grade =3
Recurring grade 2 pneumonitis, Myocarditis grade =2
Autoimmune hemolytic anemia, hemolytic uremic syndrome, acquired hemophilia grade =3
Guillain-Barre, severe peripheral or autonomic neuropathy, transverse myelitis, encephalitis, aseptic meningitis
Laboratory abnormality grade =3 for >7days (except nephritis grade 3-4, combined elevations of aspartate or alanine transaminase and total bilirubin, hyperglycemia, serum electrolytes/enzymes changes without clinical impact)
Febrile neutropenia, documented infection with absolute neutrophil count<10^9/L, grade 3 neutropenia >7days, grade 4 neutropenia or thrombocytopenia, or bleeding with platelet transfusion
AE with discontinuation >21days
Significant drug-related AE
12 months or treatment discontinuation
Secondary Proportion of patients with adverse events during the whole treatment course All adverse events during the whole treatment course 12 months or treatment discontinuation
Secondary Duration of overall response Time between the first occurrence of tumor objective response, partial or complete (RECIST 1.1) and the first radiological progression, with response assessment every 9 weeks, up to 24 months 24 months
Secondary Time to response Time between inclusion and the first occurrence of tumor objective response (complete or partial, according to RECIST 1.1) or the end of the study, with response assessment every 9 weeks, up to 24 months 24 months
Secondary Progression-free survival Time between inclusion and the date of the first radiological progression (according to RECIST 1.1), death (any cause), or last follow-up (maximum=24 months), whichever occurs first. 24 months
Secondary Overall survival Time between inclusion and death (any cause) or last follow-up (maximum=24 months), whichever occurs first 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05977998 - A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology Phase 2
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT03257163 - Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Phase 2
Completed NCT02128243 - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Phase 2
Completed NCT01178944 - Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Phase 2
Terminated NCT00209079 - Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma Phase 2
Terminated NCT02862535 - Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Phase 1
Active, not recruiting NCT05008783 - A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma Phase 3
Recruiting NCT04430738 - Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Phase 1/Phase 2
Recruiting NCT04114136 - Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies Phase 2
Completed NCT03196232 - Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer Phase 2
Recruiting NCT04047953 - Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma N/A
Completed NCT02864381 - Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Phase 2
Completed NCT02891447 - Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer Phase 2
Terminated NCT04032704 - A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Phase 2
Terminated NCT04604132 - Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Phase 1/Phase 2
Completed NCT02830594 - Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT06038578 - A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer Phase 2
Terminated NCT04099277 - A Study of LY3435151 in Participants With Solid Tumors Phase 1